American Thoracic Society International Conference
American Thoracic Society International Conference
Source/Disclosures
Source:

Snyder LD, et al. A102 – ILD Diagnosis and Monitoring. Presented at: American Thoracic Society Virtual; Aug. 5-10, 2020 (virtual meeting).

Disclosures: The IPF-PRO Registry is funded by Boehringer Ingelheim Pharmaceuticals and coordinated by the Duke Clinical Research Institute. Snyder is an employee of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals to coordinate the IPF-PRO Registry.
August 13, 2020
1 min read
Save

Delay from symptom onset to IPF diagnosis often longer than 1 year

Source/Disclosures
Source:

Snyder LD, et al. A102 – ILD Diagnosis and Monitoring. Presented at: American Thoracic Society Virtual; Aug. 5-10, 2020 (virtual meeting).

Disclosures: The IPF-PRO Registry is funded by Boehringer Ingelheim Pharmaceuticals and coordinated by the Duke Clinical Research Institute. Snyder is an employee of the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals to coordinate the IPF-PRO Registry.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In the IPF-PRO Registry, 50% of patients had a delay of longer than 1 year between symptom onset and diagnosis of idiopathic pulmonary fibrosis.

Laurie D. Snyder, MD, MHS, associate professor of medicine at Duke University School of Medicine and member of the Duke Clinical Research Institute, and colleagues analyzed data from 498 patients in the IPF-PRO Registry enrolled from June 2014 to March 2019. Patients received a first diagnosis of IPF at one of 40 IPF-PRO Registry enrolling centers in the U.S. and had medical documentation on symptom onset and/or high-resolution CT scans showing pulmonary fibrosis.

Reference: Snyder LD, et al. Am J Respir Crit Care Med. 2020;201:A2565.

Median time from IPF symptom onset to diagnosis was 13.6 months. In 50% of patients, the median time from symptom onset to diagnosis was more than 1 year, according to an e-poster from the American Thoracic Society Virtual meeting.

Median time from imaging evidence of pulmonary fibrosis to diagnosis was 3.5 months. In 21.6% of patients, time from imaging evidence to diagnosis exceeded 1 year.

Cardiac comorbidities were more frequent in patients with a longer time from symptom onset or imaging evidence of IPF to diagnosis. This included coronary artery disease, atrial fibrillation or flutter, pulmonary hypertension and prior deep vein thrombosis or pulmonary embolism.

Researchers observed no significant difference in univariable and adjusted models for time to death or lung transplant between patients with longer vs. shorter time from symptom onset to IPF diagnosis (P = .41 and P = .25, respectively) and time from imaging evidence of pulmonary fibrosis to IPF diagnosis (P = .55 and P = .24, respectively).

“Despite improved awareness of IPF, there remains a long period from symptom onset to diagnosis in a large proportion of patients,” Snyder and colleagues wrote in the e-poster. “Getting [a high-resolution CT] scan performed is a critical step in the diagnostic process.”

Reference:

Snyder LD, et al. Am J Respir Crit Care Med. 2020;201:A2565.